Silence Therapeutics plc 8-K/A

What Happened
Silence Therapeutics plc filed an amendment to its Current Report on Form 8-K on July 16, 2026 to update information previously reported in the Original Form 8-K filed December 15, 2025 under Item 5.02. The amendment discloses that material modifications were made to a material compensatory plan, contract or arrangement involving a named executive officer, and that those modifications were effected pursuant to an agreement entered into after the Original Form 8-K was filed. The company states no other changes were made to the Original Form 8-K.

Key Details

• Amendment filed: July 16, 2026 (updates Original Form 8-K dated December 15, 2025).
• Item involved: Item 5.02 (Departure of Directors or Certain Officers; Election of Directors).
• Subject: Material modifications to a material compensatory plan/contract for a named executive officer.
• Cause: Modifications were effected pursuant to an agreement entered into subsequent to the Original Form 8-K; no other changes to the Original filing.

Why It Matters
Material modifications to an executive’s compensation arrangement can affect future compensation expense, potential dilution (if equity awards are involved), and how management incentives are structured. For investors, the amendment means you should review both the Original Form 8-K and this updated disclosure to understand the precise terms and potential financial or governance impact. Look for further detail in upcoming SEC filings (e.g., proxy statements, 10-Q/10-K) if you need specifics on amounts, timing, or the identity of the officer.